-- (Updated to include BofA's commentary)
BofA Securities raised its price target on Johnson & Johnson (JNJ) to $254 from $253, while maintaining its Neutral rating after the company's reported better-than-expected Q1 results.
Given the results, the brokerage modestly raised its 2026 forecasts mainly for Tremfya (immunology). But, as there were no thesis-changing updates, with the company providing above-peer top-line growth and favorable LOE profile, which is already reflected in its premium multiple, the brokerage reiterated its Neutral rating on balanced risk/reward.
Johnson & Johnson has an average rating of overweight and mean price target of $256.39, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $237.77, Change: $-2.33, Percent Change: -0.97%